Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Completed 66 enrolled Institut du Cancer de Montpellier - Val d'Aurelle

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib administered in combination with mGEMOX in patients with advanced biliary tract cancer.

Timeline

Start: 2014-09
Primary completion: 2019-12
Completion: 2019-12

Publications

Results Blanc JF, Bouattour M, Gauthier L, Deshayes E, Guillemard S, Touchefeu Y, Portales F, Borg C, Harguem L, Guimbaud R, Mineur L, Ychou M, Mazard T, Assenat E. Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. Oncologist. 2025 Jun 4;30(6):oyaf080. doi: 10.1093/oncolo/oyaf080.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Regorafenib	Small molecule	80 mg	Oral
Subject	Regorafenib	Small molecule	120 mg	Oral
Subject	Regorafenib	Small molecule	160 mg	Oral
Background	Gemcitabine	Small molecule	900 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	80 mg/m2	Intravenous

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Summary

Timeline

Publications

Drugs

Indications